The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

7 Nov 2013 07:00

RNS Number : 4049S
Sopheon PLC
07 November 2013
 



SOPHEON PLC

("Sopheon" or the "Company")

 

INTERIM MANAGEMENT STATEMENT

 

Sopheon plc, the international provider of software and services that improve the financial return from innovation and new product development investments, issues its interim management statement for the period since 1 July 2013 to date.

 

In our interim report issued at the end of August, we reported an improvement in half year results over our solid 2012 performance, with revenues for the half year of £6.6m (2012: £6.2m) and revenue visibility for 2013 of £10.5m. Visibility today stands at £11.9m compared to £11.7m a year ago.  Meeting our commercial goals will require a strong finish to the year, and we are working to close several sales opportunities from new and existing clients to achieve this objective. As we always emphasize, our revenues are sensitive to the timing and value of individual orders.

 

We have some exciting activities and events underway in the second half of the year. We are participating in major innovation conferences for the Chemical, Food & Beverage, and Personal Care industries and have also launched a new Chemical industry webinar series. We are also participating in over a dozen other events, webinars and roundtables. Later this month we launch Accolade Release 9.0. This release introduces a new Accolade Roadmapping module, superseding Vision Strategist, an updated release of Idea Lab, and many other valuable additions and enhancements. Our third release in 2013, this reflects a fast pace of development that underpins our market position and is enabled by the Agile methodology we have adopted. Looking further ahead, we are working on a completely new website which will launch in early 2014 and will further enhance our marketing capabilities for reaching and engaging with buyers globally.

 

During the summer we implemented the first phase of the corporate restructuring. This was implemented through a two-step process involving a 10,000:1 share consolidation followed by a 1:500 share subdivision one week later. This procedure reduced the number of shares in issue by a ratio of 20, from 145.6 million shares to 7.3 million shares. It also reduced the number of shareholders on the Company's UK share register from approximately 4,000 to just over 200. This does not include shareholders in the Dutch system, which we expected to fall from over 7,000 to under 2,000. As previously noted, we have received indications that the reduction was not correctly processed by certain brokers in the Netherlands. We believe this means the Dutch shareholder count may have reduced to around 5,000. We continue to make appropriate enquiries and representations in the Netherlands, and the board will consider its options in light of the responses received. We are now working on the second phase of our restructuring, the elimination of the accumulated deficit on the profit and loss account, and expect to complete this by the end of the year.

 

A definition of how visibility is calculated was provided in our half- yearly report published on 21 August 2013. 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Josh Royston / Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEAPFKEAFDFFF
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.